Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages

Qian Wang,Yicheng Guo,Jerren Ho,David D. Ho

DOI: https://doi.org/10.1056/nejmc2410203

IF: 158.5

2024-11-18

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 19, Page 1863-1864, November 14, 2024.

medicine, general & internal

What problem does this paper attempt to address?

Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages

Tianjiao Yao,Zhenghai Ma,Ke Lan,Yicheng Guo,Lihong Liu

DOI: https://doi.org/10.1101/2024.11.08.622746

2024-11-10

Abstract:Pemivibart (Pemgarda/VYD222) was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on March 22, 2024, for COVID-19 pre-exposure prophylaxis in immunocompromised individuals. However, its efficacy and resistance against JN.1 sublineages have yet to be fully characterized. Here, we first assessed the neutralizing activity of Pemivibart against a panel of VSV-based pseudoviruses representing contemporary JN.1 sublineages, including XEC, the fastest-growing SARS-CoV-2 strain globally, in both Vero-E6 and Vero-E6-TMPRSS2-T2A-hACE2 (Vero-E6-TA) cells. We then engineered a replication-competent vesicular stomatitis virus with JN.1 spike (rVSVΔG-JN.1) to select for escape variants and performed structural analyses to comprehensively map Pemivibart's escape mutations. Our results demonstrated that Pemivibart exhibited comparable neutralization patterns in both cell lines and retains broad effectiveness against SARS-CoV-2 JN.1 sublineages tested. However, its potency was remarkably reduced against KP.3.1.1 and XEC, with IC50 values of approximately 4.2 μg/mL, about 22-fold higher than that for JN.1, as well as JN.1-derived Pemivibart-escape mutants harbouring low-frequency mutations across SARS-CoV-2 strains through mutiple antibody evasion mechanisms in Vero-E6-TA cells. Collectively, our findings underscored the importance of monitoring the clinical efficacy of Pemivibart as JN.1 sublineages continue to evolve. The escape profile of Pemivibart could provide valuable insights for forecasting and optimizing its effectiveness against emerging SARS-CoV-2 variants.

Microbiology
Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages

Qian Wang,Yicheng Guo,Jerren Ho,David D Ho

DOI: https://doi.org/10.1101/2024.08.12.607496

2024-08-19

Abstract:Protection from COVID-19 vaccination is suboptimal in many immunocompromised individuals. In March 2024, the Food and Drug Administration issued an Emergency Use Authorization for pemivibart (Permagard/VYD222), an engineered human monoclonal antibody, for pre-exposure prophylaxis in this vulnerable population. However, SARS-CoV-2 has since evolved extensively, resulting in multiple Omicron JN.1 sublineages. We therefore evaluated the in vitro neutralizing activity of pemivibart against the prevalent forms of JN.1, including KP.2, KP.3, KP.2.3, LB.1, and, importantly, KP.3.1.1, which is now expanding most rapidly. A panel of VSV-based pseudoviruses representing major JN.1 sublineages was generated to assess their susceptibility to pemivibart neutralization in vitro. Structural analyses were then conducted to understand the impact of specific spike mutations on the virus-neutralization results. Pemivibart neutralized both JN.1 and KP.2 in vitro with comparable activity, whereas its potency was decreased slightly against LB.1, KP.2.3, and KP.3 but substantially against KP.3.1.1. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 μg/mL, or ~32.7 fold higher than that of JN.1 in our study. Structural analyses suggest that Q493E and the S31-deletion mutations in viral spike contribute to the antibody evasion, with the latter having a more pronounced effect. Our findings show that pemivibart has lost substantial neutralizing activity in vitro against KP.3.1.1, the most rapidly expanding lineage of SARS-CoV-2 today. Close monitoring of its clinical efficacy is therefore warranted. These results also highlight the imperative to expand our arsenal of preventive agents to protect millions of immunocompromised individuals who could not respond robustly to COVID-19 vaccines.

Immunology
Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage

Colin Powers,Braedon Williams,Alex Kreher,Feng Gao,Brandyn West,Daniel Chupp,Robert Allen

DOI: https://doi.org/10.1101/2024.11.11.623127

2024-11-13

Abstract:Pemivibart is a monoclonal antibody therapy currently under Emergency Use Authorization for the for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents over 12 years of age with certain immunocompromised conditions. As a part of the overall monitoring strategy for the activity of pemivibart, the antibody is regularly evaluated against emerging variants of SARS-CoV-2 using pseudovirus neutralization assays. Recent clinical data from Invivyd demonstrates that the PhenoSense pseudovirus assays carried out at Monogram Biosciences have been a reliable and consistent predictor of continued pemivibart clinical activity against SARS-COV-2 variants that have predominated across the timespan that includes the CANOPY clinical trial and the post-EUA authorization period. Additionally, new potential antibodies based upon the structural framework of pemivibart are continuously under evaluation. Fifteen of these yeast-produced pemivibart-like antibodies were tested for neutralization activity against recent variants KP.3 and KP.3.1.1. Like pemivibart, all 15 maintained activity against KP.3.1.1, with the change in IC50 averaging 2.51-fold +/- 0.7 compared to KP.3. Four pemivibart-like antibodies were also tested against the XEC variant, with the change in IC50 averaging 3.01-fold compared to KP.3. These data suggest continued activity for pemivibart and pemivibart-like antibodies against KP.3.1.1 and XEC, recent variants containing N-terminal domain modifications.

Microbiology
Safety of Protease Inhibitors and Arbidol for SARS-CoV-2 Pneumonia in Zhejiang Province, China

Yong-zheng Guo,Kai-jin Xu,Yong-tao Li,Jia-dan Fu,Min Xu,Ling Yu,Ji-fang Sheng,Biao Zhu

DOI: https://doi.org/10.1631/jzus.b2000204

2020-01-01

Abstract:The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).
Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Samuel Desta Guma,Zhaoyin Zhou,Kang Song,Feipu Yang,Jin Suo,Yan Zhang,Emmanuel Mintah Bonku,Abdullajon Odilov,Guanghui Tian,Zhijian Xu,Xiangrui Jiang,Qiumeng Zhang,Weiliang Zhu,Jingshan Shen

DOI: https://doi.org/10.1016/j.ejmech.2024.117004

IF: 7.088

2024-01-01

European Journal of Medicinal Chemistry

Abstract:Given the high pathogenicity and rapid mutation rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is imperative to sustain efforts in drug research and development. Herein, we present the design, synthesis, and evaluation of peptidomimetic spiropyrrolidine derivatives as potent 3CLpro inhibitors against SARS-CoV-2. Among the synthesized derivatives, several compounds exhibited high potency in inhibiting 3CLpro, with IC50 values ranging from 21 nM to 53 nM. Notably, compounds 9b and 9h displayed improved enzymatic inhibition (IC50 = 25 nM and 21 nM, respectively) compared to nirmatrelvir (47 nM). Compound 9b showed enhanced stability in human and mouse liver microsomes compared to nirmatrelvir, whereas 9h exhibited similar stability to nirmatrelvir in both species. Furthermore, compound 9h displayed exceptional potency in cellular assays targeting the SARS-CoV-2 replicon within Huh7 cells, with a single-digit nanomolar activity that is 5.6 times better than that of nirmatrelvir. In a pharmacokinetic study in mice (PO, 20 mg/kg), compound 9h exhibited a prolonged plasma half-life (T1/2 = 2.58 h) compared to nirmatrelvir (T1/2 = 0.51 h) and demonstrated an AUC(0-t) value (1106 h∗ng/mL) equivalent to that of nirmatrelvir (1023 h∗ng/mL). These findings indicate that compound 9h is a promising lead for developing a novel 3CLpro inhibitor against SARS-CoV-2.
Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodies

Delphine Planas,Isabelle Staropoli,Cyril Planchais,Emilie Yab,Banujaa Jeyarajah,Yannis Rahou,Florence Guivel-Benhassine,Matthieu Prot,Frederic Lemoine,Vincent Enouf,Etienne Simon-Loriere,Hugo Mouquet,Marie-Anne Rameix-Welti,Olivier Schwartz

DOI: https://doi.org/10.1101/2024.08.20.608835

2024-08-21

Abstract:First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, two novel mAbs, Pemivibart and Sipavibart, have been approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized. We isolated authentic JN.1.1, KP1.1, LB.1 and KP3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in two target cell lines. Compared to ancestral strains, Pemivibart remained moderately active against JN.1 sub-variants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 ug/ml for KP3.3. Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP1.1, LB.1 and KP3.3. Our results highlight the need for a close clinical monitoring of Pemivibart and raise concerns about the clinical efficacy of Sipavibart.

Immunology
Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2

Jhen-Yi Hong,Shih-Chao Lin,Kylene Kehn-Hall,Kai-Min Zhang,Shun-Yuan Luo,Hung-Yi Wu,Sui-Yuan Chang,Ming-Hon Hou

DOI: https://doi.org/10.1016/j.bpj.2024.01.013

IF: 3.4

2024-02-21

Biophysical Journal

Abstract:Coronaviruses not only pose significant global public health threats but also cause extensive damage to livestock-based industries. Previous studies have shown that 5-benzyloxygramine (P3) targets the Middle East respiratory syndrome coronavirus (MERS-CoV) nucleocapsid (N) protein N-terminal domain (N-NTD), inducing non-native protein-protein interactions (PPIs) that impair N protein function. Moreover, P3 exhibits broad-spectrum antiviral activity against CoVs. The sequence similarity of N proteins is relatively low among CoVs, further exhibiting notable variations in the hydrophobic residue responsible for non-native PPIs in the N-NTD.

biophysics
Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants

Romel Rosales,Briana L McGovern,M Luis Rodriguez,Rocio Leiva-Rebollo,Randy Diaz-Tapia,Jared Benjamin,Devendra K Rai,Rhonda D Cardin,Annaliesa S Anderson,PSP study group,Emilia Mia Sordillo,Harm van Bakel,Viviana Simon,Adolfo García-Sastre,Kris M White,Hala Alshammary,R Banu,K Farrugia,Ana Silvia Gonzalez-Reiche,A Paniz-Mondolfi,J Polanco

DOI: https://doi.org/10.1016/j.antiviral.2024.105970

Abstract:Variants of SARS-CoV-2 pose significant challenges in public health due to their increased transmissibility and ability to evade natural immunity, vaccine protection, and monoclonal antibody therapeutics. The emergence of the highly transmissible Omicron variant and subsequent subvariants, characterized by an extensive array of over 32 mutations within the spike protein, intensifies concerns regarding vaccine evasion. In response, multiple antiviral therapeutics have received FDA emergency use approval, targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and main protease (Mpro) regions, known to have relatively fewer mutations across novel variants. In this study, we evaluated the efficacy of nirmatrelvir (PF-07321332) and other clinically significant SARS-CoV-2 antivirals against a diverse panel of SARS-CoV-2 variants, encompassing the newly identified Omicron subvariants XBB1.5 and JN.1, using live-virus antiviral assays. Our findings demonstrate that while the last Omicron subvariants exhibited heightened pathogenicity in our animal model, nirmatrelvir and other clinically relevant antivirals consistently maintained their efficacy against all tested variants, including the XBB1.5 subvariant.
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

Jared Pitts,Jiani Li,Jason K. Perry,Venice Du Pont,Nicholas Riola,Lauren Rodriguez,Xianghan Lu,Chaitanya Kurhade,Xuping Xie,Gregory Camus,Savrina Manhas,Ross Martin,Pei-Yong Shi,Tomas Cihlar,Danielle P. Porter,Hongmei Mo,Evguenia Maiorova,John P. Bilello

DOI: https://doi.org/10.1128/aac.00222-22

IF: 5.938

2022-05-10

Antimicrobial Agents and Chemotherapy

Abstract:Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of which Omicron is currently the predominant variant circulating worldwide. SARS-CoV-2 variants of concern/variants of interest (VOC/VOI) have evidence of increased viral transmission, disease severity, or decreased effectiveness of vaccines and neutralizing antibodies.

pharmacology & pharmacy,microbiology
The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice

Jie Yang,Huifen Fan,Anna Yang,Wenhui Wang,Xin Wan,Fengjie Lin,Dongsheng Yang,Jie Wu,Kaiwen Wang,Wei Li,Qian Cai,Lei You,Deqin Pang,Jia Lu,Changfu Guo,Jinrong Shi,Yan Sun,Xinguo Li,Kai Duan,Shuo Shen,Shengli Meng,Jing Guo,Zejun Wang

DOI: https://doi.org/10.3390/vaccines12070742

2024-07-03

Abstract:The emergence of SARS-CoV-2 variants of concern (VOCs) with increased transmissibility and partial resistance to neutralization by antibodies has been observed globally. There is an urgent need for an effective vaccine to combat these variants. Our study demonstrated that the B.1.351 variant inactivated vaccine candidate (B.1.351V) generated strong binding and neutralizing antibody responses in BALB/c mice against the B.1.351 virus and other SARS-CoV-2 variants after two doses within 28 days. Immunized K18-hACE2 mice also exhibited elevated levels of live virus-neutralizing antibodies against various SARS-CoV-2 viruses. Following infection with these viruses, K18-hACE2 mice displayed a stable body weight, a high survival rate, minimal virus copies in lung tissue, and no lung damage compared to the control group. These findings indicate that B.1.351V offered protection against infection with multiple SARS-CoV-2 variants in mice, providing insights for the development of a vaccine targeting SARS-CoV-2 VOCs for human use.
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Rita E. Chen,Emma S. Winkler,James Brett Case,Ishmael D. Aziati,Traci L. Bricker,Astha Joshi,Tamarand L. Darling,Baoling Ying,John M. Errico,Swathi Shrihari,Laura A. VanBlargan,Xuping Xie,Pavlo Gilchuk,Seth J. Zost,Lindsay Droit,Zhuoming Liu,Spencer Stumpf,David Wang,Scott A. Handley,W. Blaine Stine,Pei-Yong Shi,Meredith E. Davis-Gardner,Mehul S. Suthar,Miguel Garcia Knight,Raul Andino,Charles Y. Chiu,Ali H. Ellebedy,Daved H. Fremont,Sean P. J. Whelan,James E. Crowe,Lisa Purcell,Davide Corti,Adrianus C. M. Boon,Michael S. Diamond

DOI: https://doi.org/10.1038/s41586-021-03720-y

IF: 64.8

2021-06-21

Nature

Abstract:Rapidly-emerging variants jeopardize antibody-based countermeasures against SARS-CoV-2. While cell culture experiments have demonstrated loss of potency of several anti-spike neutralizing antibodies against SARS-CoV-2 variant strains1–3, the in vivo significance of these results remains uncertain. Using a panel of monoclonal antibodies (mAbs) corresponding to many in advanced clinical development by Vir Biotechnology, AbbVie, AstraZeneca, Regeneron, and Lilly, we report the impact on protection in animals against authentic SARS-CoV-2 variants including viruses with B.1.1.7, B.1.351, or B.1.1.28 spike genes. Although some individual mAbs showed reduced or abrogated neutralizing activity in cell culture against B.1.351, B.1.1.28, B.1.617.1, and B.1.526 viruses with E484 spike protein mutations, low prophylactic doses of mAb combinations protected against infection by many variants in K18-hACE2 transgenic mice, 129S2 immunocompetent mice, and hamsters without emergence of resistance. Exceptions were mAb LY-CoV555 and LY-CoV555/LY-CoV016 mono- and combination therapy, which lost all protective activity, and AbbVie 2B04/47D11, which showed partial loss of activity. When administered after infection as therapy, higher doses of several mAb cocktails protected in vivo against viruses with a B.1.351 spike gene. Thus, many, but not all, of the antibody products with Emergency Use Authorization (EUA) should retain substantial efficacy against the prevailing SARS-CoV-2 variant strains.

multidisciplinary sciences
Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine

Yasunori Fukumoto,Noriyuki Suzuki,Reina Hara,Yu-ki Tanaka,Yasumitsu Ogra

DOI: https://doi.org/10.3390/ijms25115767

IF: 5.6

2024-05-26

International Journal of Molecular Sciences

Abstract:While research has identified several inhibitors of the main protease (Mpro) of SARS-CoV-2, a significant portion of these compounds exhibit reduced activity in the presence of reducing agents, raising concerns about their effectiveness in vivo. Furthermore, the conventional biosafety level 3 (BSL-3) for cellular assays using viral particles poses a limitation for the widespread evaluation of Mpro inhibitor efficacy in a cell-based assay. Here, we established a BSL-1 compatible cellular assay to evaluate the in vivo potential of Mpro inhibitors. This assay utilizes mammalian cells expressing a tagged Mpro construct containing N-terminal glutathione S-transferase (GST) and C-terminal hemagglutinin (HA) tags and monitors Mpro autodigestion. Using this method, GC376 and boceprevir effectively inhibited Mpro autodigestion, suggesting their potential in vivo activity. Conversely, carmofur and ebselen did not exhibit significant inhibitory effects in this assay. We further investigated the inhibitory potential of selenoneine on Mpro using this approach. Computational analyses of binding energies suggest that noncovalent interactions play a critical role in facilitating the covalent modification of the C145 residue, leading to Mpro inhibition. Our method is straightforward, cost-effective, and readily applicable in standard laboratories, making it accessible to researchers with varying levels of expertise in infectious diseases.

biochemistry & molecular biology,chemistry, multidisciplinary
Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants

Tingting Li,Xiaojian Han,Chenjian Gu,Hangtian Guo,Huajun Zhang,Yingming Wang,Chao Hu,Kai Wang,Fengjiang Liu,Feiyang Luo,Yanan Zhang,Jie Hu,Wang Wang,Shenglong Li,Yanan Hao,Meiying Shen,Jingjing Huang,Yingyi Long,Shuyi Song,Ruixin Wu,Song Mu,Qian Chen,Fengxia Gao,Jianwei Wang,Shunhua Long,Luo Li,Yang Wu,Yan Gao,Wei Xu,Xia Cai,Di Qu,Zherui Zhang,Hongqing Zhang,Na Li,Qingzhu Gao,Guiji Zhang,Changlong He,Wei Wang,Xiaoyun Ji,Ni Tang,Zhenghong Yuan,Youhua Xie,Haitao Yang,Bo Zhang,Ailong Huang,Aishun Jin

DOI: https://doi.org/10.1038/s41467-021-26539-7

IF: 16.6

2021-11-02

Nature Communications

Abstract:Abstract Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of immune escape, challenging the present COVID-19 prophylaxis and clinical interventions. Here, 3 receptor binding domain (RBD) specific monoclonal antibodies (mAbs), 58G6, 510A5 and 13G9, with high neutralizing potency blocking authentic SARS-CoV-2 virus display remarkable efficacy against authentic B.1.351 virus. Surprisingly, structural analysis has revealed that 58G6 and 13G9 both recognize the steric region S 470–495 on the RBD, overlapping the E484K mutation presented in B.1.351. Also, 58G6 directly binds to another region S 450–458 in the RBD. Significantly, 58G6 and 510A5 both demonstrate prophylactic efficacy against authentic SARS-CoV-2 and B.1.351 viruses in the transgenic mice expressing human ACE2 (hACE2), protecting weight loss and reducing virus loads. Together, we have evidenced 2 potent neutralizing Abs with unique mechanism targeting authentic SARS-CoV-2 mutants, which can be promising candidates to fulfill the urgent needs for the prolonged COVID-19 pandemic.

multidisciplinary sciences
Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals

Jimena Pérez-Vargas,Gabriel Lemieux,Connor A H Thompson,Antoine Désilets,Siobhan Ennis,Guang Gao,Danielle G Gordon,Annika Lea Schulz,Masahiro Niikura,Ivan Robert Nabi,Mel Krajden,Pierre-Luc Boudreault,Richard Leduc,François Jean,Connor A.H. Thompson,Danielle G. Gordon

DOI: https://doi.org/10.1016/j.antiviral.2024.105869

IF: 7.6

2024-05-01

Antiviral Research

Abstract:SARS-CoV-2 Omicron subvariants with increased transmissibility and immune evasion are spreading globally with alarming persistence. Whether the mutations and evolution of spike (S) Omicron subvariants alter the viral hijacking of human TMPRSS2 for viral entry remains to be elucidated. This is particularly important to investigate because of the large number and diversity of mutations of S Omicron subvariants reported since the emergence of BA.1. Here we report that human TMPRSS2 is a molecular determinant of viral entry for all the Omicron clinical isolates tested in human lung cells, including ancestral Omicron subvariants (BA.1, BA.2, BA.5), contemporary Omicron subvariants (BQ.1.1, XBB.1.5, EG.5.1) and currently circulating Omicron BA.2.86. First, we used a co-transfection assay to demonstrate the endoproteolytic cleavage by TMPRSS2 of spike Omicron subvariants. Second, we found that N-0385, a highly potent TMPRSS2 inhibitor, is a robust entry inhibitor of virus-like particles harbouring the S protein of Omicron subvariants. Third, we show that N-0385 exhibits nanomolar broad-spectrum antiviral activity against live Omicron subvariants in human Calu-3 lung cells and primary patient-derived bronchial epithelial cells. Interestingly, we found that N-0385 is 10-20 times more potent than the repositioned TMPRSS2 inhibitor, camostat, against BA.5, EG.5.1, and BA.2.86. We further found that N-0385 shows broad synergistic activity with clinically approved direct-acting antivirals (DAAs), i.e., remdesivir and nirmatrelvir, against Omicron subvariants, demonstrating the potential therapeutic benefits of a multi-targeted treatment based on N-0385 and DAAs.

pharmacology & pharmacy,virology
Broad antiviral effects of Echinacea purpurea against SARS-CoV-2 variants of concern and potential mechanism of action

Selvarani Vimalanathan,Mahmoud Shehata,Kannan Sadasivam,Serena Delbue,Maria Dolci,Elena Pariani,Sarah D’Alessandro,Stephan Pleschka

DOI: https://doi.org/10.1101/2021.12.12.472255

2021-12-13

Abstract:Abstract Background SARS-CoV-2 variants of concern (VOC) represent an alarming threat as they show altered biological behavior and may escape vaccination effectiveness. Some exhibit increased pathogenicity and transmissibility compared to the original wild type WUHAN (Hu-1). Broad-spectrum antivirals could complement and further enhance preventive benefits achieved through SARS-CoV-2 vaccination campaigns Methods The anti-coronavirus activity of Echinacea purpurea (Echinaforce® extract, EF) against (i) VOCs B1.1.7 (alpha), B.1.351.1 (beta), P.1 (gamma), B1.617.2 (delta), AV.1 (Scottish) and B1.525 (eta), (ii) SARS-CoV-2 spike (S) protein-pseudotyped viral particles and reference strain OC43 as well as (iii) wild-type SARS-CoV-2 (Hu-1) were analyzed. Molecular dynamics (MD) were applied to study interaction of Echinacea’s phytochemical markers with known pharmacological viral and host cell targets. Results EF extract broadly inhibited propagation of all investigated SARS-CoV-2 VOCs as well as entry of SARS-CoV-2 pseudoparticles at EC50’s ranging from 3.62 to 12.03 μg/ml. Preventive addition of 20 μg/ml EF to epithelial cells significantly reduced sequential infection with SARS-CoV-2 (Hu-1) as well as with the common human strain OC43. MD analyses showed constant binding affinities to Hu-1, B1.1.7, B.1.351, P.1 and B1.617.2-typic S protein variants for alkylamides, caftaric acidand feruoyl-tartaric acid in EF extract. They further indicated that the EF extract could possibly interact with TMPRSS-2, a serine protease required for virus endocytosis. Conclusions EF extract demonstrated stable antiviral activity across 6 tested VOCs, which is likely due to the constant affinity of the contained phytochemical marker substances to all spike variants. A possible interaction of EF with TMPRSS-2 partially would explain cell protective benefits of the extract by inhibition of endocytosis. EF may therefore offer a supportive addition to vaccination endeavors in the control of existing and future SARS-CoV-2 virus mutations.
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19

Pete Schmidt,Yong Li,Myra Popejoy

DOI: https://doi.org/10.1056/nejmc2404555

IF: 158.5

2024-11-18

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 19, Page 1860-1862, November 14, 2024.

medicine, general & internal
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Yanmei Hu,Chunlong Ma,Tommy Szeto,Brett Hurst,Bart Tarbet,Jun Wang

DOI: https://doi.org/10.1021/acsinfecdis.0c00761

IF: 5.578

2021-03-01

ACS Infectious Diseases

Abstract:As the COVID-19 pandemic continues to unfold, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (Mpro) inhibitors including boceprevir, calpain inhibitors II and XII, and GC-376 with potent antiviral activity against infectious SARS-CoV-2 in cell culture. In this study, we further characterized the mechanism of action of these four compounds using the SARS-CoV-2 pseudovirus neutralization assay. It was found that GC-376 and calpain inhibitors II and XII have a dual mechanism of action by inhibiting both viral Mpro and host cathepsin L in Vero cells. To rule out the cell-type dependent effect, the antiviral activity of these four compounds against SARS-CoV-2 was also confirmed in type 2 transmembrane serine protease-expressing Caco-2 cells using the viral yield reduction assay. In addition, we found that these four compounds have broad-spectrum antiviral activity in inhibiting not only SARS-CoV-2 but also SARS-CoV, and MERS-CoV, as well as human coronaviruses (CoVs) 229E, OC43, and NL63. The mechanism of action is through targeting the viral Mpro, which was supported by the thermal shift-binding assay and enzymatic fluorescence resonance energy transfer assay. We further showed that these four compounds have additive antiviral effect when combined with remdesivir. Altogether, these results suggest that boceprevir, calpain inhibitors II and XII, and GC-376 might be promising starting points for further development against existing human coronaviruses as well as future emerging CoVs.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsinfecdis.0c00761?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00761</a>.Sequence alignment of coronaviruses (Figure S1); amino acid conservation among HCoVs (Table S1); enzymatic kinetic studies of HCoV Mpros in the presence or absence of inhibitors (Figure S2); cellular antiviral activity of GC-376, calpain inhibitors II and XII, and boceprevir against a panel of coronaviruses (Figure S3) (<a class="ext-link" href="/doi/suppl/10.1021/acsinfecdis.0c00761/suppl_file/id0c00761_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

chemistry, medicinal,infectious diseases
Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Wenhao Dai,Dirk Jochmans,Hang Xie,Hang Yang,Jian Li,Haixia Su,Di Chang,Jiang Wang,Jingjing Peng,Lili Zhu,Yong Nian,Rolf Hilgenfeld,Hualiang Jiang,Kaixian Chen,Leike Zhang,Yechun Xu,Johan Neyts,Hong Liu

DOI: https://doi.org/10.1021/acs.jmedchem.0c02258

IF: 8.039

2021-04-19

Journal of Medicinal Chemistry

Abstract:A novel series of peptidomimetic aldehydes was designed and synthesized to target 3C protease (3Cpro) of enterovirus 71 (EV71). Most of the compounds exhibited high antiviral activity, and among them, compound 18p demonstrated potent enzyme inhibitory activity and broad-spectrum antiviral activity on a panel of enteroviruses and rhinoviruses. The crystal structure of EV71 3Cpro in complex with 18p determined at a resolution of 1.2 Å revealed that 18p covalently linked to the catalytic Cys147 with an aldehyde group. In addition, these compounds also exhibited good inhibitory activity against the 3CLpro and the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially compound 18p (IC50 = 0.034 μM, EC50 = 0.29 μM). According to our previous work, these compounds have no reasons for concern regarding acute toxicity. Compared with AG7088, compound 18p also exhibited good pharmacokinetic properties and more potent anticoronavirus activity, making it an excellent lead for further development.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02258?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02258</a>.An overlay of EV71 3Cpro-18p and AG7088 complex structures; the binding pocket of 3Cpro of CoXB3, RV-A02, and EV71; the anti-SARS-CoV-2 activities of compounds; the 1H NMR and 13C NMR spectra of target compounds; the purity of target compounds; and the crystallography data collection and refinement statistics (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02258/suppl_file/jm0c02258_si_001.pdf">PDF</a>)Molecular formula stings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02258/suppl_file/jm0c02258_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

chemistry, medicinal
Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection

Lei Yu,Yajie Wang,Yuanchen Liu,Xiaomin Xing,Chen Li,Xun Wang,Jialu Shi,Wentai Ma,Jiayan Li,Yanjia Chen,Rui Qiao,Xiaoyu ZHAO,Ming Gao,Shuhua Wen,Yingxue Xue,Yongjun Guan,Hin Chu,Lei Sun,Pengfei Wang

DOI: https://doi.org/10.1101/2024.06.06.597720

2024-06-12

Abstract:Monoclonal antibody (mAb) therapeutics hold promise for both preventing and treating infectious diseases, especially among vulnerable populations. However, the emergence of various variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents challenges for current mAb treatments, emphasizing the need for more potent and broadly neutralizing antibodies. In this study, we employed an unbiased screening approach to discover broadly neutralizing antibodies and successfully isolated two mAbs from individuals with only exposure to ancestral SARS-CoV-2. One of these antibodies, CYFN1006-1, exhibited robust cross-neutralization against a spectrum of SARS-CoV-2 variants, including the latest JN.1 and KP.2 variants, with consistent IC50 values ranging from ~1 to 5 ng/mL. Notably, it also displayed broad neutralization activity against SARS-CoV and related sarbecoviruses, such as WIV1, SHC014, RaTG13, and GD-Pangolin. Structural analysis revealed that these mAbs target shared hotspot but mutation-resistant epitopes, with their Fabs locking the RBD in the "down" conformation through interactions with adjacent Fabs and RBDs, and cross-linking Spike trimers into di-trimers to block viral infection. In vivo studies conducted in a JN.1-infected hamster model validated the protective efficacy of CYFN1006-1, emphasizing its therapeutic potential. These findings suggest that, through meticulous approaches, rare antibodies with cross-neutralization activities against SARS-CoV-2 and related sarbecoviruses can be identified from individuals with exclusively ancestral virus exposure.

Microbiology
Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1

Nianzhen Chen,Katharina Emma Decker,Sebastian R. Schulz,Amy Kempf,Inga Nehlmeier,Anna-Sophie Moldenhauer,Alexandra Dopfer-Jablonka,Georg M. N. Behrens,Metodi V. Stankov,Luis Manthey,Hans-Martin Jäck,Markus Hoffmann,Stefan Pöhlmann,Prerna Arora

DOI: https://doi.org/10.3390/vaccines12111236

2024-10-31

Vaccines

Abstract:New SARS-CoV-2 lineages continue to evolve and may exhibit new characteristics regarding host cell entry efficiency and potential for antibody evasion. Here, employing pseudotyped particles, we compared the host cell entry efficiency, ACE2 receptor usage, and sensitivity to antibody-mediated neutralization of four emerging SARS-CoV-2 lineages, KP.2, KP.2.3, KP.3, and LB.1. The XBB.1.5 and JN.1 lineages served as controls. Our findings reveal that KP.2, KP.2.3, KP.3, and LB.1 lineages enter host cells efficiently and in an ACE2-dependent manner, and that KP.3 is more adept at entering Calu-3 lung cells than JN.1. However, the variants differed in their capacity to employ ACE2 orthologues from animal species for entry, suggesting differences in ACE2 interactions. Moreover, we demonstrate that only two out of seven therapeutic monoclonal antibody (mAbs) in preclinical development retain robust neutralizing activity against the emerging JN.1 sublineages tested, while three mAbs displayed strongly reduced neutralizing activity and two mAbs lacked neutralizing activity against any of the lineages tested. Furthermore, our results show that KP.2, KP.2.3, KP.3, and LB.1 lineages evade neutralization by antibodies induced by infection or vaccination with greater efficiency than JN.1, particularly in individuals without hybrid immunity. This study indicates that KP.2, KP.2.3, KP.3, and LB.1 differ in ACE2 interactions and the efficiency of lung cell entry and suggest that evasion of neutralizing antibodies drove the emergence of these variants.

immunology,medicine, research & experimental

Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages

Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages

Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages

Neutralization of recent SARS-CoV-2 variants by genetically and structurally related mAbs of the pemivibart lineage

Safety of Protease Inhibitors and Arbidol for SARS-CoV-2 Pneumonia in Zhejiang Province, China

Discovery of Peptidomimetic Spiropyrrolidine Derivatives As Novel 3clpro Inhibitors Against SARS-CoV-2

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodies

Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2

Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains

Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine

Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals

Broad antiviral effects of Echinacea purpurea against SARS-CoV-2 variants of concern and potential mechanism of action

Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection

Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1